

# **Novartis new analysis further showed durable and potent LDL-C reduction with inclisiran, an investigational first-in-class siRNA cholesterol-lowering treatment**

Mar 28, 2020

---

**Source URL:** <https://qa1.novartis.us/news/media-releases/novartis-new-analysis-further-showed-durable-and-potent-ldl-c-reduction-inclisiran-investigational-first-class-sirna-cholesterol-lowering-treatment-0>

## **List of links present in page**

1. <https://qa1.novartis.us/news/media-releases/novartis-new-analysis-further-showed-durable-and-potent-ldl-c-reduction-inclisiran-investigational-first-class-sirna-cholesterol-lowering-treatment-0>